These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 27208016)

  • 1. Levetiracetam for the prevention of busulfan-induced seizures in pediatric hematopoietic cell transplantation recipients.
    Floeter AE; McCune JS
    J Oncol Pharm Pract; 2017 Jul; 23(5):344-349. PubMed ID: 27208016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of levetiracetam versus phenytoin/fosphenytoin for busulfan seizure prophylaxis at a pediatric institution.
    Hughes K; Garrity L; Nelson AS; Lane A; Teusink-Cross A
    Pediatr Transplant; 2021 Jun; 25(4):e14026. PubMed ID: 33894096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levetiracetam for busulfan-induced seizure prophylaxis in children undergoing hematopoietic stem cell transplantation.
    Soni S; Skeens M; Termuhlen AM; Bajwa RP; Gross TG; Pai V
    Pediatr Blood Cancer; 2012 Oct; 59(4):762-4. PubMed ID: 22378696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of levetiracetam with phenytoin for the prevention of intravenous busulfan-induced seizures in hematopoietic cell transplantation recipients.
    Akiyama K; Kume T; Fukaya M; Shiki I; Enami T; Tatara R; Shino M; Ikeda T
    Cancer Chemother Pharmacol; 2018 Oct; 82(4):717-721. PubMed ID: 30083882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of clonazepam and levetiracetam in children for prevention of busulfan-induced seizure in hematopoietic stem cell transplantation.
    Tsujimoto SI; Shirai R; Utano T; Osumi T; Matsumoto K; Shioda Y; Kiyotani C; Uchiyama T; Deguchi T; Terashima K; Tomizawa D; Matsumoto K; Kato M
    Int J Hematol; 2020 Mar; 111(3):463-466. PubMed ID: 31863341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral levetiracetam for prevention of busulfan-induced seizures in adult hematopoietic cell transplant.
    Chaguaceda C; Aguilera-Jiménez V; Gutierrez G; Roura J; Riu G
    Int J Clin Pharm; 2020 Apr; 42(2):351-354. PubMed ID: 32026356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal prevention of seizures induced by high-dose busulfan.
    Eberly AL; Anderson GD; Bubalo JS; McCune JS
    Pharmacotherapy; 2008 Dec; 28(12):1502-10. PubMed ID: 19025431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levetiracetam versus (fos)phenytoin for seizure prophylaxis in pediatric patients with intracranial hemorrhage.
    Bansal S; Blalock D; Kebede T; Dean NP; Carpenter JL
    J Neurosurg Pediatr; 2014 Feb; 13(2):209-15. PubMed ID: 24286154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimal incidence of neurotoxicity without prophylaxis during busulfan-based conditioning regimen in patients undergoing stem cell transplantation.
    Leon-Rodriguez E; Rivera-Franco MM
    Int J Hematol; 2016 Dec; 104(6):644-646. PubMed ID: 27722893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of valproate and levetiracetam for the prevention of busulfan-induced seizures in hematopoietic stem cell transplantation.
    Nakashima T; Tanaka T; Koido K; Nishibuchi Y; Hashimoto H; Ito A; Inamoto Y; Kurosawa S; Kim SW; Fukuda T; Terakado H
    Int J Hematol; 2019 Jun; 109(6):694-699. PubMed ID: 30915718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning.
    McCune JS; Wang T; Bo-Subait K; Aljurf M; Beitinjaneh A; Bubalo J; Cahn JY; Cerny J; Chhabra S; Cumpston A; Dupuis LL; Lazarus HM; Marks DI; Maziarz RT; Norkin M; Prestidge T; Mineishi S; Krem MM; Pasquini M; Martin PJ
    Biol Blood Marrow Transplant; 2019 Jul; 25(7):1424-1431. PubMed ID: 30871976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Busulfan triggers epileptic seizures under levetiracetam and valproic acid therapy.
    Yazal Erdem A; Azık F; Tavil B; Teber S; Tunç B; Uçkan D
    Pediatr Transplant; 2014 Jun; 18(4):412-3. PubMed ID: 24645650
    [No Abstract]   [Full Text] [Related]  

  • 13. Reduced Risk of Sinusoidal Obstruction Syndrome of the Liver after Busulfan-Cyclophosphamide Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplantation.
    El-Serafi I; Remberger M; Ringdèn O; Törlén J; Sundin M; Björklund A; Winiarski J; Mattsson J
    Clin Transl Sci; 2020 Mar; 13(2):293-300. PubMed ID: 31675173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between the Magnitude of Intravenous Busulfan Exposure and Development of Hepatic Veno-Occlusive Disease in Children and Young Adults Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation.
    Bognàr T; Bartelink IH; Egberts TCG; Rademaker CMA; Versluys AB; Slatter MA; Kletzel M; Nath CE; Cuvelier GDE; Savic RM; Dvorak C; Long-Boyle JR; Cowan MJ; Bittencourt H; Bredius RGM; Güngör T; Shaw PJ; Ansari M; Hassan M; Krajinovic M; Hempel G; Marktel S; Chiesa R; Théoret Y; Lund T; Orchard PJ; Wynn RF; Boelens JJ; Lalmohamed A
    Transplant Cell Ther; 2022 Apr; 28(4):196-202. PubMed ID: 35065280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Outcomes for Pediatric Patients With Acute Myeloid Leukemia in Remission and Undergoing Allogeneic Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Based on Either Intravenous Busulfan or Total Body Irradiation: A Report From the Japanese Society for Hematopoietic Cell Transplantation.
    Ishida H; Kato M; Kudo K; Taga T; Tomizawa D; Miyamura T; Goto H; Inagaki J; Koh K; Terui K; Ogawa A; Kawano Y; Inoue M; Sawada A; Kato K; Atsuta Y; Yamashita T; Adachi S
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2141-2147. PubMed ID: 26271192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal regimen of levetiracetam for prevention of busulfan-induced seizure in patients undergoing hematopoietic stem cell transplantation: A review of available evidence.
    Tavajohi R; Shahrami B; Rostami T; Kiumarsi A; Honarmand H; Hadjibabaie M
    J Oncol Pharm Pract; 2023 Jun; 29(4):927-933. PubMed ID: 36843563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies.
    Pasquini MC; Le-Rademacher J; Zhu X; Artz A; DiPersio J; Fernandez HF; Mineishi S; Kamishohara M; Mehta J; Nakamura Y; Ratanatharathorn V; Sobecks R; Burkart J; Bredeson C
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1424-1430. PubMed ID: 27154848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levetiracetam Prophylaxis for Post-traumatic Brain Injury Seizures is Ineffective: A Propensity Score Analysis.
    Zangbar B; Khalil M; Gruessner A; Joseph B; Friese R; Kulvatunyou N; Wynne J; Latifi R; Rhee P; O'Keeffe T
    World J Surg; 2016 Nov; 40(11):2667-2672. PubMed ID: 27307089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation.
    Kletzel M; Jacobsohn D; Duerst R
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):472-9. PubMed ID: 16545731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clonazepam for seizure prophylaxis in adult patients treated with high dose busulfan.
    Diaz-Carrasco MS; Olmos R; Blanquer M; Velasco J; Sánchez-Salinas A; Moraleda JM
    Int J Clin Pharm; 2013 Jun; 35(3):339-43. PubMed ID: 23575621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.